The Valley Desk

ArticleEJHaemPublished

Efficacy and Safety of Teclistamab in Relapsed/Refractory Multiple Myeloma: 2-Year Follow-Up From MajesTEC-1 China Cohort

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
EJHaem
Published
Subject terms
Bispecific antibody; Relapsed/refractory Multiple Myeloma; Teclistamab; Majestec‐1 Study
PubMed ID
42534634
PubMed Central ID
PMC13421914
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal